Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immediate versus deferred androgen deprivation therapy in men with prostate cancer

Next Previous
Trial Profile

Immediate versus deferred androgen deprivation therapy in men with prostate cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buserelin; Cyproterone
  • Indications Prostate cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01819285).
  • 27 Mar 2013 Biomarkers information updated
  • 19 May 2011 Long-term follow-up results presented at the 106th Annual Meeting of the American Urological Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top